INM
InMed Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.38
+3.76%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$7.37M
MomentumView details →
1D Return
+3.76%
YTD Return
+29.24%
RSI (14)
43.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
Market Cap
$7.37M
RSI (14)
43.1
MomentumView details →
1D Return
+3.76%
YTD Return
+29.24%
SummaryUpdated Mar 1, 2026
InMed Pharmaceuticals Inc. (NASDAQ:INM) is a clinical-stage pharmaceutical company founded in 1981 and headquartered in Vancouver, Canada. Originally incorporated as Cannabis Technologies Inc., the company changed its name to InMed Pharmaceuticals in October 2014 and went public in May 2014. InMed focuses on developing cannabinoid-based therapies for rare diseases and has evolved from early-stage research into clinical trials, with its lead product candidate currently in Phase 2 clinical development for a rare skin condition.
Similar companies
Latest newsMore news →
InMed Pharmaceuticals and Mentari Therapeutics amended their merger agreement and filed a registration statement on Form S-4 with the SEC for their proposed all-stock merger.60d agoInMed Pharmaceuticals received notice from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing.92d ago